阿尔茨海默病及相关病2025，Vol.8Issue(4)：253-258,6.DOI:10.3969/j.issn.2096-5516.2025.04.006
激肽释放酶相关肽酶与阿尔茨海默病相关机制研究进展
Recent advances in kallikrein-related peptidases and their mechanisms in Alzheimer's disease
摘要
Abstract
Recent studies have shown that Kallikrein-related peptidases(KLKs)play crucial roles in the pathological progression of Alzheimer's disease(AD).This review systematically summarizes the latest research advances in AD-related KLKs(KLK1,KLK6,KLK7,KLK8,and KLK10).Studies have revealed that KLK6 affects amyloid-β(Aβ)generation by inhibiting α-secretase and enhancing γ-secretase activity;KLK7,as an Aβ-degrading enzyme secreted by astrocytes,shows accelerated Aβ deposition in AD model mice when deficient;KLK8 influences the PI3K/Akt/GSK-3β signaling pathway,leading to decreased Akt phosphorylation and increased GSK-3β expression,thereby promoting Tau protein hyperphosphorylation,with significantly higher expression levels observed in female AD patients compared to males.Furthermore,KLKs impair blood-brain barrier function through mechanisms including extracellular matrix protein cleavage and reduction of endothelial cell inflammation.Meanwhile,KLK6 and KLK8 exhibit significantly elevated expression levels in the cerebrospinal fluid and blood of AD patients,suggesting their potential value as biomarkers.A deeper understanding of KLKs'mechanisms in AD will provide new insights into the early diagnosis and treatment of the disease.关键词
激肽释放酶相关肽酶/阿尔茨海默病/β淀粉样蛋白/Tau蛋白过度磷酸化/血脑屏障Key words
Kallikrein-related peptidases/Alzheimer's disease/Amyloid-β/Hyperphosphorylated Tau/Blood-brain barrier分类
医药卫生引用本文复制引用
张君竹,马强..激肽释放酶相关肽酶与阿尔茨海默病相关机制研究进展[J].阿尔茨海默病及相关病,2025,8(4):253-258,6.基金项目
科技创新2030项目(2021ZD0201802) （2021ZD0201802）
2024年大连市科技创新基金-基于AI认知训练多靶点协同治疗阿尔茨海默病临床研究(2024JJ13PT052) （2024JJ13PT052）
